- Home
- FENC vs GLO Comparison
FENC vs GLO Comparison
Compare FENC & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | GLO |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.3M | 255.7M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENC | GLO |
|---|---|---|
| Price | $7.86 | $6.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 118.3K | ★ 170.5K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,790,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.68 | $4.08 |
| 52 Week High | $9.92 | $5.18 |
Technical Indicators
Market Signals| Indicator | FENC | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 58.68 |
| Support Level | $7.65 | $5.92 |
| Resistance Level | $8.11 | $6.03 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 52.61 | 73.17 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.